New cocktail shows promise against tough pancreatic cancer
NCT ID NCT06361888
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 29 times
Summary
This study tests whether adding two extra drugs (surufatinib and camrelizumab) to standard chemotherapy can help people with metastatic pancreatic cancer live longer and control their disease better. About 500 adults aged 18-75 who have not had prior treatment for their advanced cancer will take part. The goal is to see if the new combination improves overall survival and slows cancer growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nanjing Tianyinshan Hospital
NOT_YET_RECRUITINGNanjing, Jiangsu, 210000, China
Contact
-
Tianjin Cancer Hospital
RECRUITINGTianjin, Tianjin Municipality, 300000, China
Contact
Conditions
Explore the condition pages connected to this study.